Data protection Impressum

Medical Devices

ONWARD Medical has secured EUR 40.6 million through an accelerated bookbuild offering led by a EUR 25 million investment from EQT Life Sciences, extending the company's cash runway into the first quarter of 2028.

ONWARD Medical raises EUR 40 million to extend ARC therapy commercialization

20 April 2026

Lausanne-based AC Immune has amended its license and collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative diseases, with IND-enabling studies set to commence in the first half of 2026.

AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy

15 April 2026

Geneva-based dEEGtal has appointed neurotechnology entrepreneur and investor Ann Bunnenberg to its board of directors, as the AI-powered brain signal platform advances clinical studies across Switzerland, Spain, and the United States ahead of a CHF 4–5 million seed round.

dEEGtal strengthens governance and advances clinical validation across three continents

14 April 2026

Four life sciences projects were recognized at BIND – BioInnovation Day 2026, held at CHUV Lausanne on 1 April 2026, as the region's flagship academic innovation showcase drew 340 participants from academia, healthcare, industry, and investment.

BIND 2026 highlights Western Switzerland’s life sciences innovation pipeline

14 April 2026

Top Stories Western Switzerland

Top Stories from Western Switzerland (March 2026)

1 April 2026

Lausanne-based Polares Medical has closed an oversubscribed USD 50 million Series C financing round to advance clinical studies of its MRace Posterior Leaflet Replacement system for mitral regurgitation across the US, Europe, and Australia.

Polares Medical raises USD 50 million to advance its mitral valve replacement system

9 March 2026

As life sciences companies navigate increasingly complex global markets, the decision of where to establish or expand international operations has become a strategic one.

Why Life Sciences Companies Choose Switzerland to Scale Internationally

Lausanne-based Xsensio has closed an oversubscribed USD 7 million Series A financing round to accelerate clinical deployment of its Lab-on-Skin wearable biosensing platform, with new backing from WI Harper and a collaboration with Texas Instruments.

Xsensio raises USD 7 million to advance its wearable biosensing platform

3 March 2026

Renens-based L.E.S.S. SA has raised CHF 17 million to accelerate the industrial-scale deployment of its proprietary LuxiBright nano-fiber lighting technology across automotive, machine vision, and medical markets.

L.E.S.S. SA raises CHF 17 million to scale its nano-fiber lighting technology

3 March 2026

Bracco Imaging, Limula, and the University of Fribourg have launched an Innosuisse-funded research partnership to automate and reduce the cost of CAR-T cell therapy production.

Bracco, Limula and the University of Fribourg join forces to lower the cost of cell therapies

3 March 2026

1 2 3 4 5 6 … 14